<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5325">
  <stage>Registered</stage>
  <submitdate>18/09/2015</submitdate>
  <approvaldate>18/09/2015</approvaldate>
  <nctid>NCT02569476</nctid>
  <trial_identification>
    <studytitle>BGB 3111 in Combination With Obinutuzumab in Subjects With B-Cell Lymphoid Malignancies</studytitle>
    <scientifictitle>A Phase 1b Study to Assess Safety, Tolerability and Antitumor Activity of the Combination of BGB 3111 With Obinutuzumab in Subjects With B-Cell Lymphoid Malignancies</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>BGB-3111_GA101_Study_001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>B-cell Lymphoid Malignancies</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - BGB-3111 and Obinutuzumab

Experimental: BGB-3111 and obinutuzumab - In the dose-escalation part, the dose levels and regimens will be evaluated. In the indication-specific expansion cohorts, patients will be assigned to different cohorts based on histology type.


Treatment: drugs: BGB-3111 and Obinutuzumab


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of participants with adverse events</outcome>
      <timepoint>From first dose to withhin 28 days of last dose of BGB-3111</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the plasma concentration-time curve from time 0 to the time of the last measurable concentration (AUClast)</outcome>
      <timepoint>the first 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the plasma concentration-time curve from time 0 to infinity time (AUC8)</outcome>
      <timepoint>the first 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Maximum plasma concentration (Cmax)</outcome>
      <timepoint>the first 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Terminal elimination half-life (t1/2)</outcome>
      <timepoint>the first 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>BTK inhibition activity of BGB-3111 by measurement of free BTK</outcome>
      <timepoint>the first 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Tumor response</outcome>
      <timepoint>Every 12 weeks from first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Aged =18 years, able and willing to provide written informed consent and to comply
             with the study protocol.

          -  Laboratory parameters as specified below:

               -  Hematologic: Platelet count &gt;40x10^9/L (may be post-transfusion); absolute
                  neutrophil count &gt;1.0x10^9/L (growth factor use is allowed to bring pre-treatment
                  neutrophils to &gt;1.0x10^9 cells/L if marrow infiltration is involved).

               -  Hepatic: Total bilirubin &lt;3 x upper limit normal (ULN); and aspartate
                  aminotransferase (AST) and alanine transaminase (ALT) =3xULN.

               -  Renal: Creatinine clearance =50 mL/min (as estimated by the Cockcroft Gault
                  equation or as measured by nuclear medicine scan or 24 hour urine collection);
                  subjects requiring hemodialysis will be excluded.

          -  Anticipated survival of at least 6 months.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

          -  Female subjects of childbearing potential and non-sterile males must agree to practice
             at least one of the following methods of birth control with partner(s) throughout the
             study and for =3 months after discontinuing BGB-3111 or =18 months following
             obinutuzumab treatment, whichever is longer: total abstinence from sexual intercourse,
             double barrier contraception, intra uterine device (IUD) or hormonal contraceptive
             initiated at least 3 months prior to first administration of study drug.

          -  Male subjects must not donate sperm from first study drug administration, until 3
             months after BGB-3111 discontinuation or 18 months following obinutuzumab treatment,
             whichever is longer.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Known central nervous system lymphoma or leukemia.

          -  Known prolymphocytic leukemia or history of, or currently suspected, Richter's
             syndrome.

          -  Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenia purpura.

          -  History of significant cardiovascular disease.

          -  Severe or debilitating pulmonary disease.

          -  History of severe allergic or anaphylactic reactions to monoclonal antibody therapy.

          -  Prior BTK inhibitor treatment.

          -  Using medications which are strong cytochrome P450 (CYP) 3A inhibitors and strong
             CYP3A inducers.

          -  Vaccination with a live vaccine within 28 days of the initiation of treatment.

          -  Allogeneic stem cell transplantation within 6 months, or has active graft versus host
             disease (GvHD) requiring ongoing immunosuppression.

          -  Receipt of the following treatment prior to first administration of BGB 3111,
             corticosteroids given with anti-neoplastic intent within 7 days, chemotherapy or
             radiotherapy within 3 weeks, monoclonal antibody within 4 weeks.

          -  Participate in any investigational drug study within 28 days of study entry, or not
             recovered from non-hematologic toxicity of any prior chemotherapy up to = Grade 1
             (except for alopecia).

          -  History of other active malignancies within 2 years of study entry.

          -  Major surgery in the past 4 weeks.

          -  Active symptomatic fungal, bacterial and/or viral infection including evidence of
             infection with human immunodeficiency virus (HIV), human T cell lymphotropic virus
             (HTLV 1) seropositive status.

          -  Inability to comply with the study procedures.

          -  Pregnant or nursing women.

          -  Any illness or condition that in the opinion of the investigator may affect the safety
             of treatment or evaluation of any study's endpoints.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>86</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/10/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC,WA</recruitmentstate>
    <hospital>Border Medical Oncology - Albury</hospital>
    <hospital>St George Hospital - Kogarah</hospital>
    <hospital>Brisbane Clinic for Lymphoma, Myeloma and Leukaemia - Greenslopes</hospital>
    <hospital>Ashford Cancer Centre Research - Kurralta Park</hospital>
    <hospital>St Vincent's Hospital Melbourne - East Melbourne</hospital>
    <hospital>University Hospital Geelong - Geelong</hospital>
    <hospital>St Frances Xavier Cabrini Hospital - Malvern</hospital>
    <hospital>The Alfred Hospital - Melbourne</hospital>
    <hospital>Royal Perth Hospital - Perth</hospital>
    <postcode>2640 - Albury</postcode>
    <postcode>2217 - Kogarah</postcode>
    <postcode>4120 - Greenslopes</postcode>
    <postcode>5037 - Kurralta Park</postcode>
    <postcode>3002 - East Melbourne</postcode>
    <postcode>3220 - Geelong</postcode>
    <postcode>3144 - Malvern</postcode>
    <postcode>3181 - Melbourne</postcode>
    <postcode>6000 - Perth</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>BeiGene</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is evaluating the safety and preliminary efficacy of BGB-3111 in combination with
      obinutuzumab in subjects with B-cell lymphoid malignancies.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02569476</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Eric Hedrick, MD</name>
      <address />
      <phone />
      <fax />
      <email>clinicaltrials@beigene.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>